Stocks Health care TVTX
NASDAQ · Health careTravere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. brought in $651M of revenue over the twelve months to September 30, 2026, up 49.4% from a year earlier. It posted a net loss of $121.5M. At September 30, 2026 it held $123.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Travere Therapeutics, Inc.
- Net worth
- Travere Therapeutics, Inc. has a market value (market cap) of $4.9B at the latest share price, and shareholders' equity of $22.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $490.7M (+110.5% year on year), with a net loss of $25.5M. Over the 12 months to September 30, 2026: revenue $651M, net loss $121.5M.
- Cash flow
- In fiscal 2025 operations brought in $37.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Travere Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Travere Therapeutics, Inc. does
Travere Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TVTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $490.7M | -$25.5M | -$0.29 | n/a |
| 2024 | $233.2M | -$321.5M | -$4.08 | n/a |
| 2023 | $145.2M | -$111.4M | -$1.50 | -$280.7M |
| 2022 | $109.5M | -$278.5M | -$4.37 | -$186.5M |
| 2021 | $131.8M | -$180.1M | -$3.01 | -$19.9M |
| 2020 | $198.3M | -$169.4M | -$3.56 | -$49.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TVTX ranks in Health care
Latest SEC filings
What Travere Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 36% to $224.6M versus the same quarter last year; diluted EPS -$0.55 versus $0.28.
- November 2, 2026
- September 21, 2026Executive or director change8-KTravere Therapeutics announced that Bradley L. Campbell will succeed Dr. Eric Dube as President and Chief Executive Officer effective December 1, 2026.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake (5% or more) SCHEDULE 13G
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 48% to $169.6M versus the same quarter last year; diluted EPS -$0.37 versus -$0.14.
- August 4, 2026
Insider trades
What the people running Travere Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $80.1M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER, Director | Exercised options | 43,735 | $1.2M |
| October 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER, Director | Exercised options | 200,000 | $1.8M |
| October 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER, Director | Soldpre-planned (10b5-1) | 128,065 | $6.8M |
| October 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER, Director | Soldpre-planned (10b5-1) | 37,270 | $2M |
| October 15, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER, Director | Soldpre-planned (10b5-1) | 78,400 | $4.3M |
| September 17, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER, Director | Exercised options | 108,493 | $2.5M |
| September 17, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER, Director | Soldpre-planned (10b5-1) | 101,691 | $6.6M |
| September 17, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER, Director | Soldpre-planned (10b5-1) | 6,802 | $441.8K |
Who owns TVTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive | 11.9% | November 14, 2025 |
| Fmr LLC13G, passive with 1 related filers | 7.7% | August 6, 2026 |
| Vanguard Capital Management13G, passive | 5.09% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 319 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 11,324,191 | new |
| BlackRock, Inc. | 8,020,663 | +228,630 |
| Fmr LLC | 7,096,614 | -3,871,353 |
| Bank of America Corp | 4,568,341 | +3,223,230 |
| State Street Corp | 4,256,224 | -703,764 |
| Vanguard Capital Management LLC | 4,108,694 | +62,882 |
| Perceptive Advisors LLC | 3,752,574 | -389,977 |
| Nomura Asset Management International Inc. | 2,812,514 | -457,999 |
| Adage Capital Partners GP, L.L.C. | 2,569,356 | +1,592,356 |
| Geode Capital Management, LLC | 2,371,887 | +2,328 |
| Rock Springs Capital Management LP | 2,179,069 | +701,115 |
| Kynam Capital Management, LP | 2,000,000 | +430,982 |
| Stephens Investment Management Group LLC | 1,875,304 | +76,838 |
| Renaissance Technologies LLC | 1,833,079 | -133,700 |
| Emerald Advisers, LLC | 1,600,886 | +43,690 |
| Armistice Capital, LLC | 1,572,539 | -3,324,878 |
| Two Sigma Investments, LP | 1,565,656 | +57,397 |
| Vanguard Portfolio Management LLC | 1,541,617 | -167,522 |
| Goldman Sachs Group Inc | 1,535,321 | -184,400 |
| Wellington Management Group Llp | 1,533,080 | +510,808 |
Insiders
16 insiders reported holding 1,409,890 shares in total, about $73.3M at the last price.
| Holder | Shares |
|---|---|
| Dube Eric MCHIEF EXECUTIVE OFFICER, Director | 432,886 |
| Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | 117,066 |
| Reed Elizabeth EChief Legal Officer and GC | 105,389 |
| Inrig JulaEVP, Head of R&D & CMO | 100,491 |
| Rote William E.Chief Research Officer | 98,197 |
| Meckler Jeffrey ADirector | 91,500 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | 87,508 |
| Lyons Gary ADirector | 61,500 |
| Coughlin TimothyDirector | 56,250 |
| Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | 42,353 |
Questions about TVTX
What does Travere Therapeutics, Inc. do?
Travere Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TVTX. Its shares trade on NASDAQ under the ticker TVTX.
What is Travere Therapeutics, Inc.'s net worth?
Travere Therapeutics, Inc. has a market value (market cap) of $4.9B at the latest share price, and shareholders' equity of $22.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Travere Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $121.5M on revenue of $651M.
How much revenue does Travere Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Travere Therapeutics, Inc. reported revenue of $651M. That is 49.4% more than a year earlier.
When did Travere Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Travere Therapeutics, Inc.'s next earnings report?
Travere Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TVTX with
Follow TVTX
Get an email when Travere Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Travere Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.